Cargando…
Targeting neurotransmitter-mediated inflammatory mechanisms of psychiatric drugs to mitigate the double burden of multimorbidity and polypharmacy
The increased incidence of multimorbidities and polypharmacy is a major concern, particularly in the growing aging population. While polypharmacy can be beneficial, in many cases it can be more harmful than no treatment, especially in individuals suffering from psychiatric disorders, who have elevat...
Autor principal: | Matt, Stephanie M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495104/ https://www.ncbi.nlm.nih.gov/pubmed/34647105 http://dx.doi.org/10.1016/j.bbih.2021.100353 |
Ejemplares similares
-
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
por: Nikkheslat, Naghmeh
Publicado: (2021) -
Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders
por: Nettis, Maria Antonietta
Publicado: (2021) -
Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic
por: Lins, Brittney
Publicado: (2021) -
Can (immune and other) gene expression help us to treat depression?
por: Mariani, Nicole
Publicado: (2021) -
Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression
por: Sforzini, Luca
Publicado: (2021)